• Product NamePacritinib (SB1518)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityPacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.
• Target NameFLT inhibitor; JAK inhibitor; Tyrosine Kinases inhibitor
• CAS No. 937272-79-2
• Calculated MW 472.58
• Formulation C28H32N4O3
• Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year

• Research Area:Cancer
  SMILES:C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=CC(=C4)C5=NC(=NC=C5)NC(=C3)C=C2
  Pathways:Angiogenesis; Proteases/Proteasome; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors; JAK/STAT signaling; Stem Cells
  Receptor:FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3
  Boling pt:
  Melting pt:
  Solubility:DMSO:11 mg/mL warmed (23.27 mM)Ethanol:<1 mg/mL (<1 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Hart S, et al. Leukemia, 2011, 25(11), 1751-1759.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting